ライフサイエンスコーパス: sleep apnea

1 t necessary for most patients with suspected sleep apnea.

2 sis on children with more severe obstructive sleep apnea.

3 omic factors and the presence of obstructive sleep apnea.

4 etes mellitus, hypertension, and obstructive sleep apnea.

5 ejection fraction and predominantly central sleep apnea.

6 ealed increased gray matter with obstructive sleep apnea.

7 etes mellitus, hypertension, and obstructive sleep apnea.

8 rol network whose dysfunction contributes to sleep apnea.

9 atus, pack-years, systemic hypertension, and sleep apnea.

10 onitor for 1 night to assess for obstructive sleep apnea.

11 arotid body (CB) activity may be a driver of sleep apnea.

12 measurements of the severity of obstructive sleep apnea.

13 uption and adverse autonomic consequences of sleep apnea.

14 Three of the four also had sleep apnea.

15 treatment of moderate-to-severe obstructive sleep apnea.

16 testing in patients suspected of obstructive sleep apnea.

17 subjects scored at high risk for obstructive sleep apnea.

18 , 14 days of actigraphy, and measurements of sleep apnea.

19 ntribute to atherosclerosis in patients with sleep apnea.

20 n, dyslipidemia, cardiovascular disease, and sleep apnea.

21 models of care for patients with obstructive sleep apnea.

22 ed with scoring at high risk for obstructive sleep apnea.

23 ifying subjects at high risk for obstructive sleep apnea.

24 comes associated with asthma and obstructive sleep apnea.

25 s and signs for the diagnosis of obstructive sleep apnea.

26 patients with mild and moderate obstructive sleep apnea.

27 italized HF patients with moderate-to-severe sleep apnea.

28 d cognitive consequences seen in obstructive sleep apnea.

29 ted to a presymptomatic stage of obstructive sleep apnea.

30 peutic intervention for preventing CB-driven sleep apnea.

31 aberrations in their signaling could lead to sleep apnea.

32 a new pharmacologic therapy for obstructive sleep apnea.

33 l-controlled type 2 diabetes and obstructive sleep apnea.

34 l its potential for reduction of obstructive sleep apneas.

35 s index >/=25kg/m(2) (+1 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 poin

36 ion (2.94 vs 2.80, P = .75), and obstructive sleep apnea (3.29 vs 2.83, P = .50).

37 ity revenue, 48 cases of cure of obstructive sleep apnea, 44 cases of remission of type 2 diabetes me

38 QR, 4-6, vs 3; IQR, 2-5; P < .001), but less sleep apnea (578 [13.5%] vs 1264 [21.6%]; P < .001).

39 ty in a prospective study of 74,543 cases of sleep apnea (60,125 outpatient, 14,418 inpatient) from t

40 There were no differences in resolution of sleep apnea (62.6% vs 62.0%; P = .77), hypertension (47.

41 The percentage of children with obstructive sleep apnea (8.2% of caffeine group versus 11.0% of plac

42 29.7%-19.5%), dyslipidemia (14.0%-6.8%), and sleep apnea (9.6%-2.6%) was reduced.

43 highly prevalent condition and a hallmark of sleep apnea, a condition that has been associated with i

44 and referral-based prevalence of obstructive sleep apnea; accuracy of symptoms and signs for the diag

45 italized HF patients with moderate-to-severe sleep apnea, adding ASV to OMT did not improve 6-month c

46 found to have increased odds of KCN included sleep apnea (adjusted OR, 1.13; 95% CI, 1.00-1.27; P = 0

47 The association between sleep apnea and atrial fibrillation (AF) has not been ex

48 he evidence that addresses the links between sleep apnea and cardiovascular disease, and research tha

49 empirical bases for considering obstructive sleep apnea and central sleep apnea associated with Chey

50 ars of age and those with severe obstructive sleep apnea and comorbidities are not candidates for amb

51 In addition, Evening types had more sleep apnea and higher stress hormones.

52 easures showed a reduction in the effects of sleep apnea and improved quality of life.

53 isk factors included sleep disturbances (eg, sleep apnea and insomnia), mental health status (eg, pos

54 nd the common sleep disorders of obstructive sleep apnea and insomnia.

55 bone density; high prevalence of obstructive sleep apnea and its implications; prevalence of mental h

56 caffeine status, are at risk for obstructive sleep apnea and periodic limb movements in later childho

57 We evaluated associations between sleep apnea and receipt of a disability pension and mort

58 have an increased likelihood of obstructive sleep apnea and to determine whether nocturnal gastroeso

59 children with moderate to severe obstructive sleep apnea, and also that even snoring alone affects ne

60 hypertension, dyslipidemia, depression, and sleep apnea, and changes in corresponding laboratory dat

61 escribed the relationships among sleepiness, sleep apnea, and driving risk.

62 ing, obesity, diabetes mellitus, obstructive sleep apnea, and elevated blood pressure predispose to A

63 eaks, patient-ventilator asynchrony, central sleep apnea, and glottic closure.

64 headaches, gastroesophageal reflux disease, sleep apnea, and infections of the respiratory system an

65 diabetes mellitus, inflammation, obstructive sleep apnea, and others.

66 pnea (PDSA), which is considered more severe sleep apnea, and self-reported habitual snoring without

67 with obesity, moderate-to-severe obstructive sleep apnea, and serum levels of C-reactive protein (CRP

68 esophageal reflux disease, adenotonsillitis, sleep apnea, anxiety, and headaches (all P < .001).

69 events per hour) and 72 obese patients with sleep apnea (apnea-hypopnea index, 43.5 +/- 28.0 events

70 iratory control system is compromised (e.g., sleep apnea, apnea of prematurity, spinal injury, or mot

71 ciated with myocardial infarcts, obstructive sleep apneas, apneas of prematurity, Rett syndrome, and

72 ite hemodynamic effects: whereas obstructive sleep apnea appears to have an adverse effect on SV, cen

73 ars to have an adverse effect on SV, central sleep apnea appears to have little or slightly positive

74 sleep in patients suffering from obstructive sleep apnea are not well understood.

75 the diagnosis and management of obstructive sleep apnea are reviewed, as are recent guidelines perta

76 s and mechanisms of Angptl4 up-regulation in sleep apnea are unknown.

77 sidering obstructive sleep apnea and central sleep apnea associated with Cheyne-Stokes respiration as

78 Central sleep apnea associated with Cheyne-Stokes respiration pr

79 a high prevalence of obstructive and central sleep apnea associated with Cheyne-Stokes respiration.

80 Among patients with obstructive sleep apnea, both CPAP and MADs were associated with red

81 ejection fraction and predominantly central sleep apnea, but all-cause and cardiovascular mortality

82 f more symptomatic patients with obstructive sleep apnea, but its effectiveness has not been evaluate

83 es a noninvasive ventilator to treat central sleep apnea by delivering servo-controlled inspiratory p

84 t of hypertension, diabetes, and obstructive sleep apnea can reduce atrial fibrillation episodes.

85 ypes spans diabetes, renal disease, obesity, sleep apnea, cardiovascular disease, and cognitive disor

86 through 2007, we identified newly diagnosed sleep apnea cases in the database.

87 RATIONALE: Obstructive sleep apnea causes intermittent hypoxemia, hemodynamic f

88 sleep indices: apnea-hypopnea index, central sleep apnea (central apnea index, >/=5 vs. <5), central

89 seous molecule carbon monoxide (CO), exhibit sleep apnea characterized by high apnea and hypopnea ind

90 gus and scoring at high risk for obstructive sleep apnea compared with colonoscopy patients disappear

91 subjects scored at high risk for obstructive sleep apnea, compared with 42% (n = 26) of EGD subjects

92 ale sex, higher body mass index, concomitant sleep apnea, conversion to laparotomy, longer operation

93 In adults with obesity and obstructive sleep apnea, CPAP combined with a weight-loss interventi

94 Central sleep apnea (CSA) is a highly prevalent, though often un

95 (HF) and either obstructive (OSA) or central sleep apnea (CSA).

96 tion of medical comorbidities (hypertension, sleep apnea, diabetes, and hyperlipidemia), functional s

97 Only 1.3% of participants reported a sleep apnea diagnosis.

98 as no long-term effects on sleep duration or sleep apnea during childhood.

99 ed aerosolized secretions from her husband's sleep apnea equipment was historically possible.

100 ellitus, chronic kidney disease, obstructive sleep apnea, etc.

101 provides a clinical overview of Obstructive Sleep Apnea focusing on prevention, diagnosis, treatment

102 along with developments in the treatment of sleep apnea, have accumulated in recent years.

103 nsion, increased pulse pressure, obstructive sleep apnea, high-level physical training, diastolic dys

104 l factors that included obesity, obstructive sleep apnea, higher comorbidity, and use of prescription

105 struction sites in patients with obstructive sleep apnea hypopnea syndrome (OSAHS).

106 y disease, diabetes mellitus, or obstructive sleep apnea (ie, lone AF) undergoing ablation and 25 mat

107 ommendations on the diagnosis of obstructive sleep apnea in adults.

108 rapy is frequently used to treat obstructive sleep apnea in children.

109 The prevalence of sleep apnea in community-screened patients is 2% to 14%

110 uptake in the genioglossus of patients with sleep apnea in comparison with obese normal subjects wit

111 H), an animal model for studying obstructive sleep apnea in humans, depresses the afferent neurotrans

112 s a cause of hypoventilation and obstructive sleep apnea in humans.

113 Obstructive sleep apnea in infants has been associated with failure

114 E-HF (Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure) trial results.

115 in association with less severe obstructive sleep apnea in women than in men with heart failure.

116 reat central apnea (CA) occurring at night ("sleep apnea") in patients with systolic heart failure (H

117 In addition, Evening types more often had sleep apnea, independent of BMI or neck circumference.

118 her elevations in the obstructive or central sleep apnea index or the presence of Cheyne-Stokes breat

119 Obstructive sleep apnea is a common disease, responsible for daytime

120 Obstructive sleep apnea is a common disorder associated with increas

121 Sleep apnea is a common problem affecting daily function

122 Obstructive sleep apnea is a risk factor for dyslipidemia and athero

123 Obstructive sleep apnea is a state-dependent disease.

124 Obstructive sleep apnea is associated with considerable health risks

125 Obstructive sleep apnea is associated with higher levels of blood pr

126 Obstructive sleep apnea is associated with hypertension, inflammatio

127 ological research indicates that obstructive sleep apnea is associated with increases in the incidenc

128 Central sleep apnea is associated with poor prognosis and death

129 wing population of patients with obstructive sleep apnea is being referred for outpatient procedures

130 Since sleep apnea is common and frequently undiagnosed, health

131 Sleep apnea is common in hospitalized heart failure (HF)

132 Sleep apnea is highly prevalent in patients with cardiov

133 Because the prevalence of obstructive sleep apnea is lower in women than in men with heart fai

134 eural circuitry that mediates arousal during sleep apnea is not known.

135 In conclusion, inpatient sleep apnea is related to a higher risk of disability pe

136 ation of patients with suspected obstructive sleep apnea is useful for selecting patients for more de

137 Despite the high prevalence of obstructive sleep apnea, it was not associated with the risk of a he

138 f genetic factors in influencing obstructive sleep apnea, its genetic basis is still largely unknown.

139 ikely to have moderate or severe obstructive sleep apnea (LR, 0.07; 95% CI, 0.03-0.19 at threshold of

140 (pH 7.0) typically found with hypoxia during sleep apnea, M94I resulted in 37% reduction in peak INa

141 A control group without sleep apnea, matched for age, gender, and comorbidities,

142 Sleep apnea may be an independent risk factor for RVO.

143 Prior studies suggest that obstructive sleep apnea may be associated with gastroesophageal refl

144 sk factors (hypertension, diabetes mellitus, sleep apnea, obesity, excessive alcohol, smoking, hypert

145 isposition, hypertension, diabetes mellitus, sleep apnea, obesity, excessive alcohol, smoking, hypert

146 nsion, systemic hypertension associated with sleep apnea, ocular neovascularization, hereditary eryth

147 Central sleep apnea (odds ratio [OR], 2.58; 95% confidence inter

148 ysis, the most significant risk factors were sleep apnea (odds ratio [OR], 3.80; 95% CI, 1.00-14.49;

149 ty about the effects of treating obstructive sleep apnea on glycemic control in patients with type 2

150 elihood of OSA if they reported a history of sleep apnea or >/= 2 hallmarks of OSA: loud snoring, day

151 propriate, refer patients for evaluation for sleep apnea or asthma.

152 (central apnea index, >/=5 vs. <5), central sleep apnea or Cheyne-Stokes respiration, obstructive ap

153 causes of hypertension including obstructive sleep apnea or primary aldosteronism.

154 ) and Cheyne-Stokes respiration with central sleep apnea (OR, 2.27; 95% CI, 1.13-4.56), but not obstr

155 f the following: CHA2DS2-VASc score of >/=2, sleep apnea, or body mass index >30 kg/m(2).

156 ine glycemic control, those with more severe sleep apnea, or those who were adherent to therapy.

157 nd psychological issues, asthma, obstructive sleep apnea, orthopedic problems, and adverse cardiovasc

158 fluid overload, both obstructive and central sleep apnea (OSA and CSA) are common.

159 Obstructive sleep apnea (OSA) affects 8-10% of the population, is ch

160 derlying the association between obstructive sleep apnea (OSA) and Alzheimer's disease is OSA leading

161 The relationship between obstructive sleep apnea (OSA) and cardiovascular events remains uncl

162 t a positive association between obstructive sleep apnea (OSA) and glaucoma; larger, retrospective co

163 Obstructive sleep apnea (OSA) and nocturnal hypoxemia are associated

164 Risk factors for obstructive sleep apnea (OSA) and the development of subsequent card

165 ical patients who have suspected obstructive sleep apnea (OSA) at risk for postoperative respiratory

166 Treatment is needed for obstructive sleep apnea (OSA) because untreated OSA can result in se

167 Surgical success for obstructive sleep apnea (OSA) depends on identifying sites of obstru

168 Obstructive sleep apnea (OSA) has been associated with increased can

169 iation between periodontitis and obstructive sleep apnea (OSA) has been suggested.

170 mmendations on the management of obstructive sleep apnea (OSA) in adults.

171 An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and outcomes ha

172 e 1990s, estimated prevalence of obstructive sleep apnea (OSA) in the United States is 10% for mild O

173 Mild obstructive sleep apnea (OSA) is a highly prevalent disorder in adul

174 Obstructive sleep apnea (OSA) is a known risk factor for atheroscler

175 Obstructive sleep apnea (OSA) is a low-grade inflammatory disease af

176 Obstructive sleep apnea (OSA) is a risk factor for cardiovascular de

177 Obstructive sleep apnea (OSA) is a risk factor for cardiovascular de

178 Obstructive sleep apnea (OSA) is a risk factor for type 2 diabetes t

179 Obstructive sleep apnea (OSA) is a sleep disorder characterized by d

180 Obstructive sleep apnea (OSA) is a worldwide disease whose prevalenc

181 Obstructive sleep apnea (OSA) is an underdiagnosed condition charact

182 Obstructive sleep apnea (OSA) is associated with atrial remodeling,

183 Obstructive sleep apnea (OSA) is associated with cardiovascular morb

184 Obstructive sleep apnea (OSA) is associated with hypertension.

185 Although obstructive sleep apnea (OSA) is associated with impaired glucose to

186 RATIONALE: Obstructive sleep apnea (OSA) is associated with several pathophysio

187 Obstructive sleep apnea (OSA) is characterized by recurrent nocturna

188 Obstructive sleep apnea (OSA) is characterized by recurrent upper ai

189 Obstructive sleep apnea (OSA) is common in patients with coronary ar

190 Obstructive sleep apnea (OSA) is common in people with hypertension,

191 Obstructive sleep apnea (OSA) is more common among patients with ast

192 Obstructive sleep apnea (OSA) is strongly related to obesity.

193 Obstructive sleep apnea (OSA) is the most common medical disorder th

194 somnography (PSG) for diagnosing obstructive sleep apnea (OSA) is unclear.

195 It is unknown whether obstructive sleep apnea (OSA) may be a risk factor for incident card

196 Despite emerging evidence that obstructive sleep apnea (OSA) may cause metabolic disturbances indep

197 thors tested the hypothesis that obstructive sleep apnea (OSA) signs/symptoms are associated with the

198 The effect of obstructive sleep apnea (OSA) syndrome in the peripapillary retinal

199 (AF) recurrence in patients with obstructive sleep apnea (OSA) undergoing pulmonary vein isolation (P

200 Previous studies in obstructive sleep apnea (OSA) were limited by study cohorts with com

201 e recruited subjects with severe obstructive sleep apnea (OSA) who were well treated and adherent wit

202 at increased risk for developing obstructive sleep apnea (OSA), and both of these conditions are asso

203 ered the treatment of choice for obstructive sleep apnea (OSA), and studies have shown that there is

204 Childhood asthma and obstructive sleep apnea (OSA), both disorders of airway inflammation

205 Sleep abnormalities, including obstructive sleep apnea (OSA), have been associated with insulin res

206 resistant hypertension (RH) and obstructive sleep apnea (OSA), the blood pressure response to contin

207 tween floppy eyelid syndrome and obstructive sleep apnea (OSA), the diagnostic criteria of floppy eye

208 ular caliber and the severity of obstructive sleep apnea (OSA).

209 ice in patients with symptomatic obstructive sleep apnea (OSA).

210 ts, is linked to the severity of obstructive sleep apnea (OSA).

211 e most common treatment used for obstructive sleep apnea (OSA).

212 , we evaluated ten patients with obstructive sleep apnea (OSA).

213 abitus is a major determinant of obstructive sleep apnea (OSA).

214 ngue is unknown in patients with obstructive sleep apnea (OSA).

215 imaging methods in patients with obstructive sleep apnea (OSA).

216 nce of glaucoma in patients with obstructive sleep apnea (OSA).

217 diac death (SCD) associated with obstructive sleep apnea (OSA).

218 with resistant hypertension have obstructive sleep apnea (OSA).

219 erapy are commonly used to treat obstructive sleep apnea (OSA).

220 nt for patients with symptomatic obstructive sleep apnea (OSA).

221 is prevalent among patients with obstructive sleep apnea (OSA).

222 a critical pathology underlying obstructive sleep apnea (OSA).

223 lth outcomes are associated with obstructive sleep apnea (OSA).

224 ects with high and low risks for obstructive sleep apnea (OSA).

225 irway pressure for patients with obstructive sleep apnea (OSA).

226 Obstructive sleep apnea(OSA) is one of the most common sleep disorde

227 ss improvement in ACT scores was obstructive sleep apnea (P = 0.016).

228 ne of several traits involved in obstructive sleep apnea pathogenesis and may be a therapeutic target

229 Snoring is common in sleep apnea patients but is not useful for establishing

230 plan-Meier analysis revealed the tendency of sleep apnea patients toward RVO development (P = .048, l

231 ated the associations of physician-diagnosed sleep apnea (PDSA), which is considered more severe slee

232 , 13% of men and 21% of women with inpatient sleep apnea received a disability pension.

233 ignificant findings reported for obstructive sleep apnea-related physiologic traits in any population

234 ), as well as a significantly higher rate of sleep apnea remission (72.5% vs 49.3%, P < .001) and hig

235 between Barrett's esophagus and obstructive sleep apnea risk.

236 The need for obstructive sleep apnea screening in Barrett's esophagus patients wi

237 r characteristics and markers of obstructive sleep apnea severity (hypoxemia, respiratory disturbance

238 o investigate whether markers of obstructive sleep apnea severity are associated with gray matter cha

239 ential HGNS efficacy across a broad range of sleep apnea severity.

240 itive testing, the likelihood of obstructive sleep apnea should be established in the clinical examin

241 31.4; 95% CI, 30.5-32.2) than those without sleep apnea (summary BMI, 28.3; 95% CI, 27.6-29.0; P < .

242 tocols in patients with intermediate-to-high sleep apnea suspicion (most patients requiring a sleep s

243 Sequentially screened patients with sleep apnea suspicion were randomized to respiratory pol

244 uded the Epworth Sleepiness Scale (ESS), the Sleep Apnea Symptoms Questionnaire (SASQ), continuous po

245 eneral quality of life measures, obstructive sleep apnea symptoms, adherence to using continuous posi

246 he ratio of %EFV to %VAF loss decreased with sleep apnea syndrome (1.34+/-0.3 vs. 0.52+/-0.08, p<0.05

247 Obstructive sleep apnea syndrome (OSAS) and nonalcoholic fatty liver

248 ittent hypoxia (CIH) occurs with obstructive sleep apnea syndrome (OSAS) and provokes systemic endoth

249 The prevalence of obstructive sleep apnea syndrome (OSAS) in patients with nonarteriti

250 Obstructive sleep apnea syndrome (OSAS) is associated with intermitt

251 Obstructive sleep apnea syndrome (OSAS) leads to neurocognitive and

252 few studies suggesting that the obstructive sleep apnea syndrome (OSAS) may compromise optic nerve h

253 estigate the correlation between obstructive sleep apnea syndrome (OSAS) risk with periodontal diseas

254 asthma patients with concomitant obstructive sleep apnea syndrome (OSAS) seems to have a favorable im

255 s been reported in patients with obstructive sleep apnea syndrome (OSAS), and these two chronic condi

256 s a role in treating snoring and obstructive sleep apnea syndrome (OSAS).

257 ocampus-dependent cognition, and obstructive sleep apnea syndrome (OSAS).

258 rved a significant prevalence of obstructive sleep apnea syndrome in patients in waiting list for LT,

259 ting, surgical treatment for the obstructive sleep apnea syndrome in school-age children did not sign

260 Obstructive sleep apnea syndrome is a highly prevalent disease resul

261 n, 5 to 9 years of age, with the obstructive sleep apnea syndrome to early adenotonsillectomy or a st

262 Prevalence of obstructive sleep apnea syndrome was 38% before the LT, 86% at 6 mon

263 sized that, in children with the obstructive sleep apnea syndrome without prolonged oxyhemoglobin des

264 ity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory fai

265 ent (Mallampati score III or IV, obstructive sleep apnea syndrome, reduced mobility of cervical spine

266 y performed in children with the obstructive sleep apnea syndrome, yet its usefulness in reducing sym

267 thmatics with moderate to severe obstructive sleep apnea syndrome.

268 Obesity and obstructive sleep apnea tend to coexist and are associated with infl

269 likely to score at high risk for obstructive sleep apnea than patients without nocturnal reflux.

270 tudy involving 155 patients with obstructive sleep apnea that was treated at primary care practices (

271 In this review, we discuss the mechanisms of sleep apnea, the evidence that addresses the links betwe

272 nd research that has addressed the effect of sleep apnea treatment on cardiovascular disease and clin

273 Finally, we review the recent development in sleep apnea treatment options, with special consideratio

274 Among patients with obstructive sleep apnea, treatment under a primary care model compar

275 Children with obstructive sleep apnea under 3 years of age and those with severe o

276 stolic HF (LV ejection fraction </= 45%) and sleep apnea underwent beat-to-beat measurement of SV by

277 Primary care management of obstructive sleep apnea vs usual care in a specialist sleep center;

278 Prevalence of severe obstructive sleep apnea was 51% (95% confidence interval, 34-69) in

279 Outpatient sleep apnea was associated with a higher risk of receivi

280 on for identifying patients with obstructive sleep apnea was nocturnal choking or gasping (summary li

281 PDSA, a marker of more severe sleep apnea, was associated with higher risk of incident

282 emia may underlie cardiovascular sequelae of sleep apnea, we evaluated the effects of nocturnal suppl

283 ts referred for sleep evaluation, those with sleep apnea weighed more (summary body mass index, 31.4;

284 ates of scoring at high risk for obstructive sleep apnea were compared.

285 2 diabetes, hypertension, dyslipidemia, and sleep apnea were found to be significantly associated wi

286 ially screened patients with OHS with severe sleep apnea were randomized into the above-mentioned gro

287 hospitalized with HF and moderate-to-severe sleep apnea were randomized to ASV plus optimized medica

288 control) on BP in patients with obstructive sleep apnea were selected by consensus.

289 s the most reliable indicator of obstructive sleep apnea, whereas snoring is not very specific.

290 Sleep apnea, which is the periodic cessation of breathin

291 mulation device in patients with obstructive sleep apnea who had difficulty either accepting or adher

292 Responses were examined in 30 patients with sleep apnea who were implanted with an HGNS system.

293 There were no associations of inpatient sleep apnea with cancer mortality.

294 ovide evidence that treatment of obstructive sleep apnea with continuous positive airway pressure imp

295 r risk factors, the treatment of obstructive sleep apnea with CPAP, but not nocturnal supplemental ox

296 Evidence supports a causal association of sleep apnea with the incidence and morbidity of hyperten

297 Patients were screened for obstructive sleep apnea with the use of the Berlin questionnaire, an

298 tes and no previous diagnosis of obstructive sleep apnea, with a glycated hemoglobin level of 6.5-8.5

299 ring without PDSA (HS), a surrogate for mild sleep apnea, with incident AF in white, black, and Hispa

300 SRD, and that fluid removal by UF attenuates sleep apnea without altering uremic status.